by Liu Jia, Chinese Academy of Sciences

Credit: Nature Immunology (2025). DOI: 10.1038/s41590-024-02074-7

A group of scientists in China has revealed a novel mechanism whereby a short form of IL-18, generated by caspase-3 cleavage in tumor cells, activates natural killer (NK) cells to suppress tumor growth, offering new therapeutic opportunities. The research is published in the journal Nature Immunology.

The researchers included Prof. Meng Guangxun’s team from the Shanghai Institute of Immunity and Infection of the Chinese Academy of Sciences and Prof. Liu Chenying’s team from Xinhua Hospital, Shanghai Jiao Tong University School of Medicine.

The response rates in treating various solid tumors remain suboptimal, underlining the urgent need for understanding tumor evading mechanisms and developing innovative treatment strategies.

NK cells are being increasingly recognized for their potential in cancer immunotherapy due to their rapid response, broad anti-tumor activity, and minimal toxicity. However, tumors employ various mechanisms to evade immune surveillance, such as reducing the expression of key immune modulators including IL-18.

IL-18 is produced as an inactive precursor (pro-IL-18) and requires cleavage by caspase-1 to become the mature, active form. The mature IL-18 is secreted from immune cells and activates immune cells for tumor control through IL-18 receptor-mediated signal. However, this process is often compromised by a decoy receptor IL-18 binding protein (IL-18BP).

In this study, researchers focused on IL-18. They discovered that tumor cells can produce a novel short form of IL-18 via caspase-3 cleavage, which is independent of the traditional mature IL-18 pathway. Unlike mature IL-18, this short form does not exit the cell but enters the nucleus, where it promotes the phosphorylation of STAT1 and ISG15 secretion, which in turn enhances NK cell anti-tumor function.

This discovery is particularly relevant in colorectal cancer, wherein the short IL-18 is negatively correlated with tumor progression in clinical samples. Intriguingly, short IL-18 promotes NK cell anti-tumor activity by modulating key signaling pathways, offering a novel and unexpected mechanism through which IL-18 can enhance immune responses in the tumor microenvironment.

“This finding challenges our previous understanding of IL-18. By identifying the role of short IL-18 in activating NK cells, it opens up new possibilities for developing targeted immunotherapies that may complement existing treatments.” said Prof. Meng.

This study advances the understanding of IL-18’s role in cancer immunotherapy, and suggests that new therapeutic strategies can be developed to enhance the efficacy of NK cell-based immunotherapies.

More information: Junchen Shen et al, Short IL-18 generated by caspase-3 cleavage mobilizes NK cells to suppress tumor growth, Nature Immunology (2025). DOI: 10.1038/s41590-024-02074-7

Journal information:Nature Immunology

Provided by Chinese Academy of Sciences

---

Explore further

Key enzyme identified as potential target for cancer immunotherapy